Login / Signup

Comparative Genomic Hybridization to Microarrays in Fetuses with High-Risk Prenatal Indications: Polish Experience with 7400 Pregnancies.

Katarzyna KowalczykMagdalena Bartnik-GłaskaMarta SmykIzabela PlaskotaJoanna BernaciakMarta KędziorBarbara Wiśniowiecka-KowalnikMarta DeperasJustyna DomaradzkaAlicja ŁuszczekDaria DutkiewiczAgata KozarDominika GradMagdalena NiemiecKamila ZiemkiewiczRóża MagdziakNatalia Braun-WalickaArtur BarczykMaciej GeremekJennifer CastañedaAnna Kutkowska-KaźmierczakPaweł WłasienkoKrystyna Jakubów-DurskaMarzena DebskaAnna M Kucinska-ChahwanSzymon KozłowskiBoyana MikulskaTadeusz IssatTomasz RoszkowskiAgnieszka Nawara-BaranAgata RungeAnna Jakubiuk-TomaszukAnna KruczekEwa KostykGrzegorz PietrasJanusz LimonJerzy ZwolińskiKarolina OchmanTomasz SzajnerMalgorzata Swiatkowska-FreudMirosław WielgośMaria SąsiadekEwa ObersztynBeata Anna Nowakowska
Published in: Genes (2022)
The aim of this study was to determine the suitability of the comparative genomic hybridization to microarray (aCGH) technique for prenatal diagnosis, but also to assess the frequency of chromosomal aberrations that may lead to fetal malformations but are not included in the diagnostic report. We present the results of the aCGH in a cohort of 7400 prenatal cases, indicated for invasive testing due to ultrasound abnormalities, high-risk for serum screening, thickened nuchal translucency, family history of genetic abnormalities or congenital abnormalities, and advanced maternal age (AMA). The overall chromosomal aberration detection rate was 27.2% (2010/7400), including 71.2% (1431/2010) of numerical aberrations and 28.8% (579/2010) of structural aberrations. Additionally, the detection rate of clinically significant copy number variants (CNVs) was 6.8% (505/7400) and 0.7% (57/7400) for variants of unknown clinical significance. The detection rate of clinically significant submicroscopic CNVs was 7.9% (334/4204) for fetuses with structural anomalies, 5.4% (18/336) in AMA, 3.1% (22/713) in the group of abnormal serum screening and 6.1% (131/2147) in other indications. Using the aCGH method, it was possible to assess the frequency of pathogenic chromosomal aberrations, of likely pathogenic and of uncertain clinical significance, in the groups of cases with different indications for an invasive test.
Keyphrases